AOD-9604 Peptide: Research Guide to Mechanism and Fat Metabolism Studies

The AOD-9604 peptide occupies an interesting niche in peptide research. Scientists specifically engineered it to isolate one effect of human growth hormone — its influence on fat metabolism — while leaving out the broader hormonal effects of full-length HGH. This guide covers what AOD-9604 is, how researchers believe it works, and what the research record shows, drawing on the original metabolic studies of the fragment.

We intend this article for qualified researchers and for educational purposes only. AOD-9604 is not for human consumption.

What Is AOD-9604?

The AOD-9604 peptide (Anti-Obesity Drug-9604) is a modified synthetic fragment corresponding to amino acids 176-191 of the human growth hormone (hGH) molecule. The literature often calls it “hGH fragment 176-191.” Researchers isolated this specific fragment because it corresponds to the region of the HGH molecule that drives lipolytic (fat-metabolizing) activity, without the region responsible for HGH’s growth-promoting and insulin-related effects.

In other words, scientists designed AOD-9604 as a research tool to study one specific piece of HGH’s biological activity in isolation, rather than as a copy of the full hormone.

Mechanism of Action

The proposed mechanism for AOD-9604 centers on adipocyte (fat cell) metabolism:

Lipolysis stimulation. Research models suggest AOD-9604 may stimulate the breakdown of stored fat (lipolysis) by acting on beta-3 adrenergic receptor pathways in adipose tissue.

Inhibition of lipogenesis. Alongside promoting fat breakdown, some studies indicate AOD-9604 may also inhibit the formation of new fat stores (lipogenesis). Researchers theorize this could compound its metabolic effects in animal models.

No reported effect on IGF-1 or blood glucose. AOD-9604 excludes the region of HGH that drives growth and insulin-related effects. Research to date has generally not linked it to the IGF-1 or blood glucose increases that full-length growth hormone causes. This isolation of effect is the core premise behind why scientists developed the fragment in the first place.

What the Research Shows

AOD-9604’s research history is notable because it’s one of the few peptides in this category to have gone through formal clinical trial phases:

• Preclinical metabolic studies examined AOD-9604’s effects on adipocyte lipolysis and lipogenesis in animal and in-vitro models, forming the basis for the fragment’s original development.
• Human clinical trials for obesity took place in the mid-2000s. Patients generally tolerated the compound well in these trials, but it did not demonstrate the efficacy needed for approval as an obesity treatment. Developers discontinued that specific indication.
• Regulatory recognition in Australia — Australia’s Therapeutic Goods Administration (TGA) has evaluated AOD-9604 and permits its use as an ingredient in certain listed products under specific regulatory categories, distinct from full drug approval.

For current researchers, AOD-9604 remains a useful tool compound specifically for studying isolated lipolytic pathways, separate from broader growth-hormone signaling.

Handling AOD-9604 in the Lab

Like other research peptides, the AOD-9604 peptide requires careful handling to preserve its structure and activity. Find full documentation on our AOD-9604 research peptide page:

• Storage (lyophilized): Store in a freezer, protected from light and moisture, until ready for reconstitution.
• Reconstitution: Reconstitute with bacteriostatic water, introducing it slowly along the interior wall of the vial rather than directly onto the lyophilized powder.
• Post-reconstitution: Refrigerate and use within your protocol’s specified timeframe; avoid repeated freeze-thaw cycles, which can degrade peptide integrity.
• Documentation: Request a Certificate of Analysis (CoA) confirming purity via HPLC and identity via mass spectrometry for each batch used in a study.

Frequently Asked Questions

Is AOD-9604 the same as HGH? No. AOD-9604 is a small synthetic fragment representing only a portion of the HGH sequence (amino acids 176-191) — specifically the region researchers study for its role in fat metabolism, not the full growth hormone molecule.

Did AOD-9604 get approved as a weight-loss drug? No. It went through clinical trials for obesity in the 2000s but did not demonstrate sufficient efficacy for drug approval. Developers discontinued that pathway.

Why do researchers still study AOD-9604? Because it’s a useful tool for isolating and studying the lipolytic (fat-metabolizing) activity that HGH drives, separate from HGH’s broader hormonal and growth-related effects. That isolation is valuable for basic metabolic research.

The Bottom Line

Researchers best understand AOD-9604 as a research tool built around a specific hypothesis: that they could isolate HGH’s fat-metabolizing activity from its other effects. It didn’t pan out as an approved obesity drug, but that same targeted mechanism is exactly what keeps it a compound of continued interest in adipocyte and lipid metabolism research.

We provide this content for informational and educational purposes only; it does not constitute medical advice. Warehouse Peptides sells its products strictly for laboratory research use, not for human or animal consumption.